EMA recommends approval of mepolizumab for eosinophilic granulomatosis with polyangiitis
medwireNews: The indication for mepolizumab should be extended to include eosinophilic granulomatosis with polyangiitis (EGPA), recommends the EMA.
Previously approved in the European Union for the treatment of eosinophilic asthma, the interleukin-5 inhibitor may now be used as an add-on treatment for people aged 6 years and older with relapsing-remitting or refractory EGPA. At present, the majority of patients with this condition are treated with corticosteroids.
The EMA’s recommendation for approval is based on a randomized controlled trial involving adults only, and the agency has requested that a post-approval safety study of mepolizumab in children aged 6-17 years with EGPA is carried out.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group